A PHASE IIIB, OPEN-LABEL, SINGLE-ARM, SINGLE-DOSE, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF GENE REPLACEMENT THERAPY WITH INTRAVENOUS OAV101 (AVXS-101) IN PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)
- Registry ID
- COAV101A12306
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2022-07-15
- Last update
- 2021-06-24
Conditions
Related clinical trials
- A TWO-PART, SEAMLESS, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7204239 IN COMBINATION WITH RISDIPLAM (RO7034067) IN PATIENTS WITH SPINAL MUSCULAR ATROPHY
- A LONG-TERM EXTENSION STUDY OF NUSINERSEN (BIIB058) ADMINISTERED AT HIGHER DOSES IN PARTICIPANTS WITH SPINAL MUSCULAR ATROPHY WHO PREVIOUSLY PARTICIPATED IN AN INVESTIGATIONAL STUDY WITH NUSINERSEN
- A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY OF CK 2127107 IN TWO ASCENDING DOSE COHORTS OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)
- A, PILOT, OPEN-LABEL, DOSE-RESPONSE STUDY INVESTIGATING THE EFFECT OF LOW-DOSE CELECOXIB ON SMN2 IN PATIENTS WITH SPINAL MUSCULAR ATROPHY
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, SHAM-PROCEDURE CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY AND SAFETY OF ISIS 396443 ADMINISTERED INTRATHECALLY IN PATIENTS WITH INFANTILE-ONSET SPINAL MUSCULAR ATROPHY
View on source registry